context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The Company has recorded a valuation allowance of $ 855 million on its foreign tax credit (“FTC”) carryover of $ 1.0 billion as of December 31, 2024, resulting in an FTC net deferred tax asset of approximately $ 153 million. The FTCs are attributable to the Macau Special Gaming Tax, which is 35% of gross gaming revenue in Macau. The Company believes payment of the Macau Special Gaming Tax qualifies as a tax paid in lieu of an income tax that is creditable against U.S. taxes. While the Company generally does not expect to generate new FTC carryovers after the year ended December 31, 2017, it will be able to utilize its existing FTC carryovers only to the extent it has active foreign source income during the applicable 10 -year FTC carryforward period. The Company relies on future U.S.-source operating income in assessing, | text | 153 | monetaryItemType | text: <entity> 153 </entity> <entity type> monetaryItemType </entity type> <context> The Company has recorded a valuation allowance of $ 855 million on its foreign tax credit (“FTC”) carryover of $ 1.0 billion as of December 31, 2024, resulting in an FTC net deferred tax asset of approximately $ 153 million. The FTCs are attributable to the Macau Special Gaming Tax, which is 35% of gross gaming revenue in Macau. The Company believes payment of the Macau Special Gaming Tax qualifies as a tax paid in lieu of an income tax that is creditable against U.S. taxes. While the Company generally does not expect to generate new FTC carryovers after the year ended December 31, 2017, it will be able to utilize its existing FTC carryovers only to the extent it has active foreign source income during the applicable 10 -year FTC carryforward period. The Company relies on future U.S.-source operating income in assessing, </context> | us-gaap:DeferredTaxAssetsLiabilitiesNet |
At December 31, 2024, gross foreign net operating loss carryforwards consisted primarily of a complementary tax exempt net operating loss (“NOL”) carryforward of $ 1.3 billion at MGM Grand Paradise resulting from non-gaming operations that will expire if not utilized in years 2025 through 2027. | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2024, gross foreign net operating loss carryforwards consisted primarily of a complementary tax exempt net operating loss (“NOL”) carryforward of $ 1.3 billion at MGM Grand Paradise resulting from non-gaming operations that will expire if not utilized in years 2025 through 2027. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2024, there is a $ 174 million valuation allowance on certain foreign deferred tax assets, which relates primarily to MGM Grand Paradise’s NOLs. | text | 174 | monetaryItemType | text: <entity> 174 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, there is a $ 174 million valuation allowance on certain foreign deferred tax assets, which relates primarily to MGM Grand Paradise’s NOLs. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
The Company has NOLs in some of the states in which it operates that total $ 234 million as of December 31, 2024, which equates to deferred tax assets of $ 14 million after federal tax effect and before valuation allowance. The NOL carryforwards in most of the states will expire, if not utilized, between 2025 through 2042. Otherwise, the NOL carryforward can be carried forward indefinitely. The Company has provided a valuation allowance of $ 12 million on some of its state deferred tax assets for the NOLs described above. | text | 234 | monetaryItemType | text: <entity> 234 </entity> <entity type> monetaryItemType </entity type> <context> The Company has NOLs in some of the states in which it operates that total $ 234 million as of December 31, 2024, which equates to deferred tax assets of $ 14 million after federal tax effect and before valuation allowance. The NOL carryforwards in most of the states will expire, if not utilized, between 2025 through 2042. Otherwise, the NOL carryforward can be carried forward indefinitely. The Company has provided a valuation allowance of $ 12 million on some of its state deferred tax assets for the NOLs described above. </context> | us-gaap:OperatingLossCarryforwards |
The Company has NOLs in some of the states in which it operates that total $ 234 million as of December 31, 2024, which equates to deferred tax assets of $ 14 million after federal tax effect and before valuation allowance. The NOL carryforwards in most of the states will expire, if not utilized, between 2025 through 2042. Otherwise, the NOL carryforward can be carried forward indefinitely. The Company has provided a valuation allowance of $ 12 million on some of its state deferred tax assets for the NOLs described above. | text | 14 | monetaryItemType | text: <entity> 14 </entity> <entity type> monetaryItemType </entity type> <context> The Company has NOLs in some of the states in which it operates that total $ 234 million as of December 31, 2024, which equates to deferred tax assets of $ 14 million after federal tax effect and before valuation allowance. The NOL carryforwards in most of the states will expire, if not utilized, between 2025 through 2042. Otherwise, the NOL carryforward can be carried forward indefinitely. The Company has provided a valuation allowance of $ 12 million on some of its state deferred tax assets for the NOLs described above. </context> | us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal |
The Company has NOLs in some of the states in which it operates that total $ 234 million as of December 31, 2024, which equates to deferred tax assets of $ 14 million after federal tax effect and before valuation allowance. The NOL carryforwards in most of the states will expire, if not utilized, between 2025 through 2042. Otherwise, the NOL carryforward can be carried forward indefinitely. The Company has provided a valuation allowance of $ 12 million on some of its state deferred tax assets for the NOLs described above. | text | 12 | monetaryItemType | text: <entity> 12 </entity> <entity type> monetaryItemType </entity type> <context> The Company has NOLs in some of the states in which it operates that total $ 234 million as of December 31, 2024, which equates to deferred tax assets of $ 14 million after federal tax effect and before valuation allowance. The NOL carryforwards in most of the states will expire, if not utilized, between 2025 through 2042. Otherwise, the NOL carryforward can be carried forward indefinitely. The Company has provided a valuation allowance of $ 12 million on some of its state deferred tax assets for the NOLs described above. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
. The Company leases the real estate assets of Bellagio from a venture in which it has a 5 % ownership interest (the “Bellagio REIT Venture”). The Bellagio lease commenced November 15, 2019 and has an initial term of 30 years with two 10 -year renewal periods, exercisable at the Company’s option, with a fixed 2 % rent escalator for the first 10 years and, thereafter, an escalator equal to the greater of 2 % and the CPI increase during the prior year, subject to a cap of 3 % during the 11th through 20th years and 4 % thereafter. Annual cash rent payments for the lease year that commenced on December 1, 2024 increased to $ 270 million as a result of the 2 % fixed annual escalator. | text | 5 | percentItemType | text: <entity> 5 </entity> <entity type> percentItemType </entity type> <context> . The Company leases the real estate assets of Bellagio from a venture in which it has a 5 % ownership interest (the “Bellagio REIT Venture”). The Bellagio lease commenced November 15, 2019 and has an initial term of 30 years with two 10 -year renewal periods, exercisable at the Company’s option, with a fixed 2 % rent escalator for the first 10 years and, thereafter, an escalator equal to the greater of 2 % and the CPI increase during the prior year, subject to a cap of 3 % during the 11th through 20th years and 4 % thereafter. Annual cash rent payments for the lease year that commenced on December 1, 2024 increased to $ 270 million as a result of the 2 % fixed annual escalator. </context> | us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners |
As of December 31, 2024 and 2023, operating lease ROU assets, net included $ 3.4 billion and $ 3.5 billion related to the Bellagio lease, respectively. | text | 3.4 | monetaryItemType | text: <entity> 3.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, operating lease ROU assets, net included $ 3.4 billion and $ 3.5 billion related to the Bellagio lease, respectively. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
As of December 31, 2024 and 2023, operating lease ROU assets, net included $ 3.4 billion and $ 3.5 billion related to the Bellagio lease, respectively. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, operating lease ROU assets, net included $ 3.4 billion and $ 3.5 billion related to the Bellagio lease, respectively. </context> | us-gaap:OperatingLeaseRightOfUseAsset |
As of December 31, 2024 and 2023, operating lease liabilities – long-term included $ 3.8 billion related to the Bellagio lease. As of December 31, 2024, operating lease liabilities – current included $ 3 million related to the Bellagio lease. | text | 3 | monetaryItemType | text: <entity> 3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024 and 2023, operating lease liabilities – long-term included $ 3.8 billion related to the Bellagio lease. As of December 31, 2024, operating lease liabilities – current included $ 3 million related to the Bellagio lease. </context> | us-gaap:OperatingLeaseLiabilityCurrent |
In connection with this cybersecurity issue, the Company became subject to consumer class actions in U.S. federal and state courts. These class actions assert a variety of common law and statutory claims based on allegations that the Company failed to use reasonable security procedures and practices to safeguard customers’ personal information, and seek monetary and statutory damages, injunctive relief and other related relief. The Company reached a settlement for $ 45 million to resolve the purported civil class action litigation related to the 2023 cybersecurity issue and a 2019 cybersecurity issue, which was paid by insurance carriers into a settlement fund in February 2025. In addition, the Company is the subject of investigations by state and federal regulators, which also could result in monetary fines and other relief. The Company cannot predict the timing or outcome of any of these potential matters, or whether the Company may be subject to additional legal proceedings, claims, regulatory inquiries, investigations, or enforcement actions. While the Company believes it is reasonably possible that it may incur losses ass | text | 45 | monetaryItemType | text: <entity> 45 </entity> <entity type> monetaryItemType </entity type> <context> In connection with this cybersecurity issue, the Company became subject to consumer class actions in U.S. federal and state courts. These class actions assert a variety of common law and statutory claims based on allegations that the Company failed to use reasonable security procedures and practices to safeguard customers’ personal information, and seek monetary and statutory damages, injunctive relief and other related relief. The Company reached a settlement for $ 45 million to resolve the purported civil class action litigation related to the 2023 cybersecurity issue and a 2019 cybersecurity issue, which was paid by insurance carriers into a settlement fund in February 2025. In addition, the Company is the subject of investigations by state and federal regulators, which also could result in monetary fines and other relief. The Company cannot predict the timing or outcome of any of these potential matters, or whether the Company may be subject to additional legal proceedings, claims, regulatory inquiries, investigations, or enforcement actions. While the Company believes it is reasonably possible that it may incur losses ass </context> | us-gaap:PaymentsForLegalSettlements |
In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. | text | 1 | monetaryItemType | text: <entity> 1 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. | text | 125 | monetaryItemType | text: <entity> 125 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. | text | 700 | monetaryItemType | text: <entity> 700 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. | text | 87 | monetaryItemType | text: <entity> 87 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the issuance of the gaming concession in January 2023, bank guarantees were provided to the government of Macau in the amount of MOP 1 billion (approximately $ 125 million as of December 31, 2024) to warrant the fulfillment of labor liabilities and of damages or losses that may result if there is noncompliance with the concession. The guarantees expire 180 days after the end of the concession term. As of December 31, 2024, MOP 700 million of the bank guarantees (approximately $ 87 million as of December 31, 2024) were secured by pledged cash. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
The Company provides a shortfall guarantee of the $ 3.01 billion principal amount of indebtedness (and any interest accrued and unpaid thereon) of the landlord of Bellagio, Bellagio REIT Venture, which is a VIE and a related party, for which such indebtedness matures in 2029. The terms of the shortfall guarantee provide that after the lenders have exhausted certain remedies to collect on the obligations under the indebtedness, the Company would then be responsible for any shortfall between the value of the collateral, which is the real estate assets of the applicable property owned by the landlord, and the debt obligation. The guarantee is accounted for under ASC 460 at fair value; such value is immaterial. | text | 3.01 | monetaryItemType | text: <entity> 3.01 </entity> <entity type> monetaryItemType </entity type> <context> The Company provides a shortfall guarantee of the $ 3.01 billion principal amount of indebtedness (and any interest accrued and unpaid thereon) of the landlord of Bellagio, Bellagio REIT Venture, which is a VIE and a related party, for which such indebtedness matures in 2029. The terms of the shortfall guarantee provide that after the lenders have exhausted certain remedies to collect on the obligations under the indebtedness, the Company would then be responsible for any shortfall between the value of the collateral, which is the real estate assets of the applicable property owned by the landlord, and the debt obligation. The guarantee is accounted for under ASC 460 at fair value; such value is immaterial. </context> | us-gaap:GuaranteeObligationsMaximumExposure |
The Company provides for guarantees (1) in the amount of 12.65 billion yen (approximately $ 80 million as of December 31, 2024) for | text | 12.65 | monetaryItemType | text: <entity> 12.65 </entity> <entity type> monetaryItemType </entity type> <context> The Company provides for guarantees (1) in the amount of 12.65 billion yen (approximately $ 80 million as of December 31, 2024) for </context> | us-gaap:GuaranteeObligationsMaximumExposure |
The Company provides for guarantees (1) in the amount of 12.65 billion yen (approximately $ 80 million as of December 31, 2024) for | text | 80 | monetaryItemType | text: <entity> 80 </entity> <entity type> monetaryItemType </entity type> <context> The Company provides for guarantees (1) in the amount of 12.65 billion yen (approximately $ 80 million as of December 31, 2024) for </context> | us-gaap:GuaranteeObligationsMaximumExposure |
of Osaka IR KK’s obligations to Osaka under various agreements related to the venture’s development of an integrated resort in Osaka, Japan and (2) of an uncapped amount to provide funding to Osaka IR KK, if necessary, for the completion of the construction and full opening of the integrated resort. The guarantees expire when the obligations relating to the full opening of the integrated resort are fulfilled. The guarantees are accounted for under ASC 460 at fair value; such value is immaterial. Additionally, the Company’s ownership interest in Osaka IR KK, which had a carrying value of $ 274 million as of December 31, 2024, is pledged as collateral for Osaka IR KK’s obligations under its credit agreement. | text | 274 | monetaryItemType | text: <entity> 274 </entity> <entity type> monetaryItemType </entity type> <context> of Osaka IR KK’s obligations to Osaka under various agreements related to the venture’s development of an integrated resort in Osaka, Japan and (2) of an uncapped amount to provide funding to Osaka IR KK, if necessary, for the completion of the construction and full opening of the integrated resort. The guarantees expire when the obligations relating to the full opening of the integrated resort are fulfilled. The guarantees are accounted for under ASC 460 at fair value; such value is immaterial. Additionally, the Company’s ownership interest in Osaka IR KK, which had a carrying value of $ 274 million as of December 31, 2024, is pledged as collateral for Osaka IR KK’s obligations under its credit agreement. </context> | us-gaap:EquityMethodInvestments |
The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. | text | 271 | monetaryItemType | text: <entity> 271 </entity> <entity type> monetaryItemType </entity type> <context> The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. </context> | us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted |
The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. | text | 1.7 | monetaryItemType | text: <entity> 1.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. </context> | us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted |
The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. | text | 25.2 | monetaryItemType | text: <entity> 25.2 </entity> <entity type> monetaryItemType </entity type> <context> The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. </context> | us-gaap:PaymentsToAcquireEquityMethodInvestments |
The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. | text | 157 | monetaryItemType | text: <entity> 157 </entity> <entity type> monetaryItemType </entity type> <context> The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. </context> | us-gaap:PaymentsToAcquireEquityMethodInvestments |
The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. | text | 10.3 | monetaryItemType | text: <entity> 10.3 </entity> <entity type> monetaryItemType </entity type> <context> The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. </context> | us-gaap:PaymentsToAcquireEquityMethodInvestments |
The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. | text | 69 | monetaryItemType | text: <entity> 69 </entity> <entity type> monetaryItemType </entity type> <context> The Company has commitments to fund Osaka IR KK for its proportionate share of the unfinanced portion of Osaka IR KK’s development project, of which an estimated amount of approximately 271 billion yen (approximately $ 1.7 billion as of December 31, 2024) remains to be funded as of December 31, 2024. The amount and timing of funding is expected to change as a result of inflation and other factors, which change is subject to ongoing negotiations with contractors and other stakeholders. During the years ended December 31, 2024 and 2023, the Company funded 25.2 billion yen (approximately $ 157 million) and 10.3 billion yen (approximately $ 69 million), respectively, of the committed amount to Osaka IR KK. </context> | us-gaap:PaymentsToAcquireEquityMethodInvestments |
During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. | text | 76 | sharesItemType | text: <entity> 76 </entity> <entity type> sharesItemType </entity type> <context> During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodShares |
During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. | text | 2.8 | monetaryItemType | text: <entity> 2.8 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodValue |
During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. | text | 4.5 | sharesItemType | text: <entity> 4.5 </entity> <entity type> sharesItemType </entity type> <context> During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodShares |
During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. | text | 202.5 | monetaryItemType | text: <entity> 202.5 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2022, the Company repurchased approximately 76 million shares of its common stock for an aggregate amount of $ 2.8 billion, which included the February 2022 repurchase of 4.5 million shares for an aggregate amount of $ 202.5 million from funds managed by Corvex Management LP, a related party. Repurchased shares were retired. During the year ended December 31, 2022, the Company completed its February 2020 $ 3.0 billion stock repurchase plan. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodValue |
During the year ended December 31, 2023, the Company repurchased approximately 54 million shares of its common stock for an aggregate amount of $ 2.3 billion. Repurchased shares were retired. In connection with these repurchases, the March 2022 $ 2.0 billion stock repurchase plan was completed. | text | 54 | sharesItemType | text: <entity> 54 </entity> <entity type> sharesItemType </entity type> <context> During the year ended December 31, 2023, the Company repurchased approximately 54 million shares of its common stock for an aggregate amount of $ 2.3 billion. Repurchased shares were retired. In connection with these repurchases, the March 2022 $ 2.0 billion stock repurchase plan was completed. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodShares |
During the year ended December 31, 2023, the Company repurchased approximately 54 million shares of its common stock for an aggregate amount of $ 2.3 billion. Repurchased shares were retired. In connection with these repurchases, the March 2022 $ 2.0 billion stock repurchase plan was completed. | text | 2.3 | monetaryItemType | text: <entity> 2.3 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2023, the Company repurchased approximately 54 million shares of its common stock for an aggregate amount of $ 2.3 billion. Repurchased shares were retired. In connection with these repurchases, the March 2022 $ 2.0 billion stock repurchase plan was completed. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodValue |
During the year ended December 31, 2024, the Company repurchased approximately 33 million shares of its common stock for an aggregate amount of $ 1.4 billion. Repurchased shares were retired. In connection with these repurchases, the February 2023 $ 2.0 billion stock repurchase plan was completed. As of December 31, 2024 the remaining availability under the November 2023 $ 2.0 billion stock repurchase plan was $ 826 million. | text | 33 | sharesItemType | text: <entity> 33 </entity> <entity type> sharesItemType </entity type> <context> During the year ended December 31, 2024, the Company repurchased approximately 33 million shares of its common stock for an aggregate amount of $ 1.4 billion. Repurchased shares were retired. In connection with these repurchases, the February 2023 $ 2.0 billion stock repurchase plan was completed. As of December 31, 2024 the remaining availability under the November 2023 $ 2.0 billion stock repurchase plan was $ 826 million. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodShares |
During the year ended December 31, 2024, the Company repurchased approximately 33 million shares of its common stock for an aggregate amount of $ 1.4 billion. Repurchased shares were retired. In connection with these repurchases, the February 2023 $ 2.0 billion stock repurchase plan was completed. As of December 31, 2024 the remaining availability under the November 2023 $ 2.0 billion stock repurchase plan was $ 826 million. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company repurchased approximately 33 million shares of its common stock for an aggregate amount of $ 1.4 billion. Repurchased shares were retired. In connection with these repurchases, the February 2023 $ 2.0 billion stock repurchase plan was completed. As of December 31, 2024 the remaining availability under the November 2023 $ 2.0 billion stock repurchase plan was $ 826 million. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodValue |
During the year ended December 31, 2024, the Company repurchased approximately 33 million shares of its common stock for an aggregate amount of $ 1.4 billion. Repurchased shares were retired. In connection with these repurchases, the February 2023 $ 2.0 billion stock repurchase plan was completed. As of December 31, 2024 the remaining availability under the November 2023 $ 2.0 billion stock repurchase plan was $ 826 million. | text | 826 | monetaryItemType | text: <entity> 826 </entity> <entity type> monetaryItemType </entity type> <context> During the year ended December 31, 2024, the Company repurchased approximately 33 million shares of its common stock for an aggregate amount of $ 1.4 billion. Repurchased shares were retired. In connection with these repurchases, the February 2023 $ 2.0 billion stock repurchase plan was completed. As of December 31, 2024 the remaining availability under the November 2023 $ 2.0 billion stock repurchase plan was $ 826 million. </context> | us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 |
Subsequent to December 31, 2024, the Company repurchased approximately 9 million shares of its common stock for an aggregate amount of $ 307 million, excluding excise tax. Repurchased shares were retired. | text | 9 | sharesItemType | text: <entity> 9 </entity> <entity type> sharesItemType </entity type> <context> Subsequent to December 31, 2024, the Company repurchased approximately 9 million shares of its common stock for an aggregate amount of $ 307 million, excluding excise tax. Repurchased shares were retired. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodShares |
Subsequent to December 31, 2024, the Company repurchased approximately 9 million shares of its common stock for an aggregate amount of $ 307 million, excluding excise tax. Repurchased shares were retired. | text | 307 | monetaryItemType | text: <entity> 307 </entity> <entity type> monetaryItemType </entity type> <context> Subsequent to December 31, 2024, the Company repurchased approximately 9 million shares of its common stock for an aggregate amount of $ 307 million, excluding excise tax. Repurchased shares were retired. </context> | us-gaap:StockRepurchasedAndRetiredDuringPeriodValue |
On May 4, 2022, the MGM Resorts 2022 Omnibus Incentive Plan (“2022 Omnibus Plan”) was approved and replaced and superseded the amended and restated MGM Resorts 2005 Omnibus Incentive Plan. The Company’s 2022 Omnibus Plan allows it to grant up to approximately 18 million shares or stock-based awards, such as stock options, stock appreciation rights (“SARs”), restricted stock units (“RSUs”), | text | 18 | sharesItemType | text: <entity> 18 </entity> <entity type> sharesItemType </entity type> <context> On May 4, 2022, the MGM Resorts 2022 Omnibus Incentive Plan (“2022 Omnibus Plan”) was approved and replaced and superseded the amended and restated MGM Resorts 2005 Omnibus Incentive Plan. The Company’s 2022 Omnibus Plan allows it to grant up to approximately 18 million shares or stock-based awards, such as stock options, stock appreciation rights (“SARs”), restricted stock units (“RSUs”), </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
As of December 31, 2024, the Company had an aggregate of approximately 14 million shares of common stock available for grant as stock-based awards under the 2022 Omnibus Plan. Additionally, as of December 31, 2024, the Company had approximately 6 million aggregate RSUs and PSUs outstanding, including deferred share units and dividend equivalent units related to RSUs and PSUs. | text | 14 | sharesItemType | text: <entity> 14 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, the Company had an aggregate of approximately 14 million shares of common stock available for grant as stock-based awards under the 2022 Omnibus Plan. Additionally, as of December 31, 2024, the Company had approximately 6 million aggregate RSUs and PSUs outstanding, including deferred share units and dividend equivalent units related to RSUs and PSUs. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
As of December 31, 2024, the Company had an aggregate of approximately 14 million shares of common stock available for grant as stock-based awards under the 2022 Omnibus Plan. Additionally, as of December 31, 2024, the Company had approximately 6 million aggregate RSUs and PSUs outstanding, including deferred share units and dividend equivalent units related to RSUs and PSUs. | text | 6 | sharesItemType | text: <entity> 6 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2024, the Company had an aggregate of approximately 14 million shares of common stock available for grant as stock-based awards under the 2022 Omnibus Plan. Additionally, as of December 31, 2024, the Company had approximately 6 million aggregate RSUs and PSUs outstanding, including deferred share units and dividend equivalent units related to RSUs and PSUs. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber |
. Pursuant to its collective bargaining agreements referenced above, the Company also contributes to UNITE HERE Health (the “Health Fund”), which provides healthcare benefits to its active and retired members. The Company contributed $ 237 million, $ 230 million, and $ 218 million to the Health Fund for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 237 | monetaryItemType | text: <entity> 237 </entity> <entity type> monetaryItemType </entity type> <context> . Pursuant to its collective bargaining agreements referenced above, the Company also contributes to UNITE HERE Health (the “Health Fund”), which provides healthcare benefits to its active and retired members. The Company contributed $ 237 million, $ 230 million, and $ 218 million to the Health Fund for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:MultiemployerPlanPensionSignificantEmployerContributionCost |
. Pursuant to its collective bargaining agreements referenced above, the Company also contributes to UNITE HERE Health (the “Health Fund”), which provides healthcare benefits to its active and retired members. The Company contributed $ 237 million, $ 230 million, and $ 218 million to the Health Fund for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 230 | monetaryItemType | text: <entity> 230 </entity> <entity type> monetaryItemType </entity type> <context> . Pursuant to its collective bargaining agreements referenced above, the Company also contributes to UNITE HERE Health (the “Health Fund”), which provides healthcare benefits to its active and retired members. The Company contributed $ 237 million, $ 230 million, and $ 218 million to the Health Fund for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:MultiemployerPlanPensionSignificantEmployerContributionCost |
. Pursuant to its collective bargaining agreements referenced above, the Company also contributes to UNITE HERE Health (the “Health Fund”), which provides healthcare benefits to its active and retired members. The Company contributed $ 237 million, $ 230 million, and $ 218 million to the Health Fund for the years ended December 31, 2024, 2023, and 2022, respectively. | text | 218 | monetaryItemType | text: <entity> 218 </entity> <entity type> monetaryItemType </entity type> <context> . Pursuant to its collective bargaining agreements referenced above, the Company also contributes to UNITE HERE Health (the “Health Fund”), which provides healthcare benefits to its active and retired members. The Company contributed $ 237 million, $ 230 million, and $ 218 million to the Health Fund for the years ended December 31, 2024, 2023, and 2022, respectively. </context> | us-gaap:MultiemployerPlanPensionSignificantEmployerContributionCost |
On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA® development program. | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA® development program. </context> | us-gaap:ProceedsFromDivestitureOfBusinesses |
On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA® development program. | text | 200.0 | monetaryItemType | text: <entity> 200.0 </entity> <entity type> monetaryItemType </entity type> <context> On March 31, 2021, we completed the sale of our oncology business to Servier Pharmaceuticals, LLC, or Servier, which represented a discontinued operation. The transaction included the sale of our oncology business, including TIBSOVO®, our clinical-stage product candidates vorasidenib, AG-270 and AG-636, and our oncology research programs for a payment of approximately $ 1.8 billion in cash at the closing, subject to certain adjustments, and a payment of $ 200.0 million in cash, if, prior to January 1, 2027, vorasidenib is granted new drug application, or NDA, approval from the FDA with an approved label that permits vorasidenib’s use as a single agent for the adjuvant treatment of patients with Grade 2 glioma that have an isocitrate dehydrogenase 1 or 2 mutation (and, to the extent required by such approval, the vorasidenib companion diagnostic test is granted an FDA premarket approval), as well as a royalty of 5 % of U.S. net sales of TIBSOVO® from the close of the transaction through loss of exclusivity, and a royalty of 15 % of U.S. net sales of vorasidenib from the first commercial sale of vorasidenib through loss of exclusivity. Servier also acquired our co-commercialization rights for Bristol Myers Squibb’s IDHIFA® and the right to receive a $ 25.0 million potential milestone payment under our prior collaboration agreement with Celgene Corporation, or Celgene, and following the sale Servier will conduct certain clinical development activities within the IDHIFA® development program. </context> | us-gaap:GainContingencyUnrecordedAmount |
As of December 31, 2023, we had cash, cash equivalents and marketable securities of $ 806.4 million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. | text | 806.4 | monetaryItemType | text: <entity> 806.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had cash, cash equivalents and marketable securities of $ 806.4 million. Although we have incurred recurring losses and expect to continue to incur losses for the foreseeable future, we expect our cash, cash equivalents and marketable securities to be sufficient to fund current operations for at least the next twelve months from the issuance of the financial statements. If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves. </context> | us-gaap:CashCashEquivalentsAndShortTermInvestments |
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. Our chief operating decision maker is the chief executive officer. Our chief operating decision maker and we view our operations and manage our business as one operating segment. | text | one | integerItemType | text: <entity> one </entity> <entity type> integerItemType </entity type> <context> Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker or decision-making group in making decisions on how to allocate resources and assess performance. Our chief operating decision maker is the chief executive officer. Our chief operating decision maker and we view our operations and manage our business as one operating segment. </context> | us-gaap:NumberOfOperatingSegments |
There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the year ended December 31, 2023. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> There were no transfers between Level 1 and Level 2 and we had no financial assets or liabilities that were classified as Level 3 at any point during the year ended December 31, 2023. </context> | us-gaap:FairValueNetAssetLiability |
At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. | text | 151 | integerItemType | text: <entity> 151 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. </context> | us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions |
At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. | text | 259 | integerItemType | text: <entity> 259 </entity> <entity type> integerItemType </entity type> <context> At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. </context> | us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions |
At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. | text | 513.5 | monetaryItemType | text: <entity> 513.5 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. </context> | us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition |
At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. | text | 868.2 | monetaryItemType | text: <entity> 868.2 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023 and 2022, we held 151 and 259 debt securities, respectively, that were in an unrealized loss position for less than one year. We did no t record an allowance for credit losses as of December 31, 2023 and 2022 related to these securities. The aggregate fair value of debt securities in an unrealized loss position at December 31, 2023 and 2022 was $ 513.5 million and $ 868.2 million, respectively. There were no individual securities that were in a significant unrealized loss position as of December 31, 2023 and 2022. We regularly review the securities in an unrealized loss position and evaluate the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. We do not consider these marketable securities to be impaired as of December 31, 2023 and 2022. </context> | us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition |
In arriving at the operating lease liabilities as of December 31, 2023, we applied the weighted-average incremental borrowing rate of 5.7 % from inception over a weighted-average remaining lease term of 4.2 years. In arriving at the operating lease liabilities as of December 31, 2022, we applied the weighted-average incremental borrowing rate of 5.7 % over a weighted-average remaining lease term of 5.2 years. | text | 5.7 | percentItemType | text: <entity> 5.7 </entity> <entity type> percentItemType </entity type> <context> In arriving at the operating lease liabilities as of December 31, 2023, we applied the weighted-average incremental borrowing rate of 5.7 % from inception over a weighted-average remaining lease term of 4.2 years. In arriving at the operating lease liabilities as of December 31, 2022, we applied the weighted-average incremental borrowing rate of 5.7 % over a weighted-average remaining lease term of 5.2 years. </context> | us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent |
We provided our landlord a security deposit of $ 2.9 million as security for our leases, which is included within other non-current assets on our consolidated balance sheet. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> We provided our landlord a security deposit of $ 2.9 million as security for our leases, which is included within other non-current assets on our consolidated balance sheet. </context> | us-gaap:LettersOfCreditOutstandingAmount |
We recorded operating sublease income of $ 6.1 million and $ 4.1 million for the years ended December 31, 2023 and December 31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $ 1.2 million which is recorded within other non-current assets on our consolidated balance sheet. | text | 6.1 | monetaryItemType | text: <entity> 6.1 </entity> <entity type> monetaryItemType </entity type> <context> We recorded operating sublease income of $ 6.1 million and $ 4.1 million for the years ended December 31, 2023 and December 31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $ 1.2 million which is recorded within other non-current assets on our consolidated balance sheet. </context> | us-gaap:SubleaseIncome |
We recorded operating sublease income of $ 6.1 million and $ 4.1 million for the years ended December 31, 2023 and December 31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $ 1.2 million which is recorded within other non-current assets on our consolidated balance sheet. | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> We recorded operating sublease income of $ 6.1 million and $ 4.1 million for the years ended December 31, 2023 and December 31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $ 1.2 million which is recorded within other non-current assets on our consolidated balance sheet. </context> | us-gaap:SubleaseIncome |
We recorded operating sublease income of $ 6.1 million and $ 4.1 million for the years ended December 31, 2023 and December 31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $ 1.2 million which is recorded within other non-current assets on our consolidated balance sheet. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> We recorded operating sublease income of $ 6.1 million and $ 4.1 million for the years ended December 31, 2023 and December 31, 2022, respectively, in other income, net in the consolidated statements of operations. We received a security deposit from our sublessee of approximately $ 1.2 million which is recorded within other non-current assets on our consolidated balance sheet. </context> | us-gaap:SecurityDepositLiability |
As of December 31, 2023, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,004,551 , and we had 4,989,341 shares available for future issuance under the 2023 Plan. | text | 12004551 | sharesItemType | text: <entity> 12004551 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2023, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,004,551 , and we had 4,989,341 shares available for future issuance under the 2023 Plan. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
As of December 31, 2023, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,004,551 , and we had 4,989,341 shares available for future issuance under the 2023 Plan. | text | 4989341 | sharesItemType | text: <entity> 4989341 </entity> <entity type> sharesItemType </entity type> <context> As of December 31, 2023, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,004,551 , and we had 4,989,341 shares available for future issuance under the 2023 Plan. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 14.32 | perShareItemType | text: <entity> 14.32 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 15.64 | perShareItemType | text: <entity> 15.64 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 31.20 | perShareItemType | text: <entity> 31.20 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 0.3 | monetaryItemType | text: <entity> 0.3 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. | text | 8.5 | monetaryItemType | text: <entity> 8.5 </entity> <entity type> monetaryItemType </entity type> <context> The weighted-average grant date fair value of options granted was $ 14.32 , $ 15.64 and $ 31.20 during the years ended December 31, 2023, 2022 and 2021, respectively. The total intrinsic value of options exercised was $ 2.9 million, $ 0.3 million and $ 8.5 million during the years ended December 31, 2023, 2022 and 2021, respectively. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
At December 31, 2023, the total unrecognized compensation expense related to unvested stock option awards was $ 27.8 million, which we expect to recognize over a weighted-average period of approximately 2.40 years. | text | 27.8 | monetaryItemType | text: <entity> 27.8 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023, the total unrecognized compensation expense related to unvested stock option awards was $ 27.8 million, which we expect to recognize over a weighted-average period of approximately 2.40 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions |
As of December 31, 2023, there was approximately $ 22.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.75 years. | text | 22.6 | monetaryItemType | text: <entity> 22.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, there was approximately $ 22.6 million of total unrecognized compensation expense related to RSUs, which we expect to be recognized over a weighted-average period of 1.75 years. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
Included in unvested shares were 145,023 shares with performance-based vesting criteria that were considered probable of achievement at December 31, 2023 and vested in January 2024. Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates. As of December 31, 2023, there was no unrecognized compensation expense related to PSUs with performance- | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> Included in unvested shares were 145,023 shares with performance-based vesting criteria that were considered probable of achievement at December 31, 2023 and vested in January 2024. Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates. As of December 31, 2023, there was no unrecognized compensation expense related to PSUs with performance- </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
As of December 31, 2023, there was no remaining unrecognized compensation expense related to MSUs. | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, there was no remaining unrecognized compensation expense related to MSUs. </context> | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. | text | 509091 | sharesItemType | text: <entity> 509091 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. | text | 112832 | sharesItemType | text: <entity> 112832 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. | text | 104867 | sharesItemType | text: <entity> 104867 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. | text | 2363636 | sharesItemType | text: <entity> 2363636 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee |
In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. | text | 1686039 | sharesItemType | text: <entity> 1686039 </entity> <entity type> sharesItemType </entity type> <context> In June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. On January 1, 2023, the annual increase for the 2013 ESPP resulted in an additional 509,091 shares authorized for issuance. We issued 112,832 shares and 104,867 shares during the years ended December 31, 2023 and 2022, respectively, under the 2013 ESPP. The 2013 ESPP provides participating employees with the opportunity to purchase up to an aggregate of 2,363,636 shares of our common stock. As of December 31, 2023, we had 1,686,039 shares available for future issuance under the 2013 ESPP. </context> | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model. | text | zero | percentItemType | text: <entity> zero </entity> <entity type> percentItemType </entity type> <context> We have never paid, and do not anticipate paying, any cash dividends in the foreseeable future, and, therefore, use an expected dividend yield of zero in the option-pricing model. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. The Company capitalized research and experimental costs of $ 232.7 million and $ 261.4 million for the years ended December 31, 2023 and December 31, 2022, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. | text | 232.7 | monetaryItemType | text: <entity> 232.7 </entity> <entity type> monetaryItemType </entity type> <context> The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. The Company capitalized research and experimental costs of $ 232.7 million and $ 261.4 million for the years ended December 31, 2023 and December 31, 2022, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. </context> | us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts |
The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. The Company capitalized research and experimental costs of $ 232.7 million and $ 261.4 million for the years ended December 31, 2023 and December 31, 2022, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. | text | 261.4 | monetaryItemType | text: <entity> 261.4 </entity> <entity type> monetaryItemType </entity type> <context> The Tax Cuts and Jobs Act (TCJA) requires taxpayers to capitalize and amortize research and experimental expenditures under Internal Revenue Code section 174 for tax years beginning after December 31, 2021. The Company capitalized research and experimental costs of $ 232.7 million and $ 261.4 million for the years ended December 31, 2023 and December 31, 2022, respectively. We will amortize these costs for tax purposes over 5 years if the research and experimentation was performed in the U.S. and over 15 years if the research and experimentation was performed outside the U.S. </context> | us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts |
As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. | text | 131.7 | monetaryItemType | text: <entity> 131.7 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. | text | 502.4 | monetaryItemType | text: <entity> 502.4 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. | text | 65.2 | monetaryItemType | text: <entity> 65.2 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. </context> | us-gaap:OperatingLossCarryforwards |
As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. | text | 25.5 | monetaryItemType | text: <entity> 25.5 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. </context> | us-gaap:TaxCreditCarryforwardAmount |
As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. | text | 28.1 | monetaryItemType | text: <entity> 28.1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. </context> | us-gaap:TaxCreditCarryforwardAmount |
As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. | text | 132.9 | monetaryItemType | text: <entity> 132.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had net operating loss carryforwards, or NOLs, available to reduce federal, state and foreign income taxes of approximately $ 131.7 million, $ 502.4 million and $ 65.2 million, respectively. At December 31, 2023, we also had available research and development tax credits for federal and state income tax purposes of approximately $ 25.5 million and $ 28.1 million, respectively. If not utilized, the credits begin to expire in 2039 and 2027 for federal and state income tax purposes, respectively. We engaged in clinical testing activities and incurred expenses that qualify for the federal orphan drug tax credit. At December 31, 2023, we had available orphan drug tax credits for federal purposes only of approximately $ 132.9 million. If not utilized, the orphan drug credits begin to expire in 2035. </context> | us-gaap:TaxCreditCarryforwardAmount |
As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. | text | 379.7 | monetaryItemType | text: <entity> 379.7 </entity> <entity type> monetaryItemType </entity type> <context> As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. | text | 296.0 | monetaryItemType | text: <entity> 296.0 </entity> <entity type> monetaryItemType </entity type> <context> As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. </context> | us-gaap:DeferredTaxAssetsValuationAllowance |
As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. | text | 83.7 | monetaryItemType | text: <entity> 83.7 </entity> <entity type> monetaryItemType </entity type> <context> As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. | text | 59.5 | monetaryItemType | text: <entity> 59.5 </entity> <entity type> monetaryItemType </entity type> <context> As required by ASC 740, we have evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets. Based on the weight of available evidence, both positive and negative, we recorded a valuation allowance of $ 379.7 million and $ 296.0 million as of December 31, 2023 and December 31, 2022, respectively, because we have determined that it is more likely than not that these assets will not be fully realized. The valuation allowance increased by $ 83.7 million for the year ended December 31, 2023 and by $ 59.5 million for the year ended December 31, 2022 primarily due to the Section 174 R&D expense capitalization. </context> | us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount |
We will recognize interest and penalties related to uncertain tax positions above the line as an expense to continuing operations. As of December 31, 2023 and 2022, we had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. If all of the Company’s unrecognized tax benefits as of December 31, 2023 were to become recognizable in the future, we would record $ 28.6 million of unrecognized tax benefits. The uncertain tax position does not impact our effective income tax rate due to the full valuation allowance. | text | 28.6 | monetaryItemType | text: <entity> 28.6 </entity> <entity type> monetaryItemType </entity type> <context> We will recognize interest and penalties related to uncertain tax positions above the line as an expense to continuing operations. As of December 31, 2023 and 2022, we had no accrued interest or penalties related to uncertain tax positions and no such amounts have been recognized. If all of the Company’s unrecognized tax benefits as of December 31, 2023 were to become recognizable in the future, we would record $ 28.6 million of unrecognized tax benefits. The uncertain tax position does not impact our effective income tax rate due to the full valuation allowance. </context> | us-gaap:UnrecognizedTaxBenefits |
Depreciation expense for the years ended December 31, 2023, 2022 and 2021 was $ 6.6 million, $ 8.4 million and $ 8.8 million, respectively. | text | 6.6 | monetaryItemType | text: <entity> 6.6 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense for the years ended December 31, 2023, 2022 and 2021 was $ 6.6 million, $ 8.4 million and $ 8.8 million, respectively. </context> | us-gaap:Depreciation |
Depreciation expense for the years ended December 31, 2023, 2022 and 2021 was $ 6.6 million, $ 8.4 million and $ 8.8 million, respectively. | text | 8.4 | monetaryItemType | text: <entity> 8.4 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense for the years ended December 31, 2023, 2022 and 2021 was $ 6.6 million, $ 8.4 million and $ 8.8 million, respectively. </context> | us-gaap:Depreciation |
Depreciation expense for the years ended December 31, 2023, 2022 and 2021 was $ 6.6 million, $ 8.4 million and $ 8.8 million, respectively. | text | 8.8 | monetaryItemType | text: <entity> 8.8 </entity> <entity type> monetaryItemType </entity type> <context> Depreciation expense for the years ended December 31, 2023, 2022 and 2021 was $ 6.6 million, $ 8.4 million and $ 8.8 million, respectively. </context> | us-gaap:Depreciation |
On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. </context> | us-gaap:StockRepurchaseProgramAuthorizedAmount1 |
On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. | text | 7.1 | sharesItemType | text: <entity> 7.1 </entity> <entity type> sharesItemType </entity type> <context> On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. </context> | us-gaap:TreasuryStockSharesAcquired |
On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. | text | 344.5 | monetaryItemType | text: <entity> 344.5 </entity> <entity type> monetaryItemType </entity type> <context> On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. </context> | us-gaap:TreasuryStockValueAcquiredCostMethod |
On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. | text | 48.38 | perShareItemType | text: <entity> 48.38 </entity> <entity type> perShareItemType </entity type> <context> On March 25, 2021, we announced that our board of directors authorized a repurchase program, or the Repurchase Program, for the repurchase of up to $ 1.2 billion of our outstanding shares of common stock. On March 31, 2021, in connection with the Repurchase Program, we entered into a definitive share repurchase agreement with BMS to repurchase 7.1 million shares of our common stock held by certain subsidiaries of BMS for an aggregate purchase price of $ 344.5 million, or $ 48.38 per share. This repurchase was completed on April 5, 2021. </context> | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. | text | 600.0 | monetaryItemType | text: <entity> 600.0 </entity> <entity type> monetaryItemType </entity type> <context> Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. </context> | us-gaap:StockRepurchaseProgramAuthorizedAmount1 |
Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. | text | 9.1 | sharesItemType | text: <entity> 9.1 </entity> <entity type> sharesItemType </entity type> <context> Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. </context> | us-gaap:TreasuryStockSharesAcquired |
Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. | text | 458.0 | monetaryItemType | text: <entity> 458.0 </entity> <entity type> monetaryItemType </entity type> <context> Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. </context> | us-gaap:TreasuryStockValueAcquiredCostMethod |
Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. | text | 50.35 | perShareItemType | text: <entity> 50.35 </entity> <entity type> perShareItemType </entity type> <context> Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. </context> | us-gaap:TreasuryStockAcquiredAverageCostPerShare |
Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. | text | 16.2 | sharesItemType | text: <entity> 16.2 </entity> <entity type> sharesItemType </entity type> <context> Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. </context> | us-gaap:TreasuryStockSharesAcquired |
Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. | text | 802.5 | monetaryItemType | text: <entity> 802.5 </entity> <entity type> monetaryItemType </entity type> <context> Further, on April 2, 2021, in connection with the Repurchase Program, we entered into a Rule 10b5-1 repurchase plan to which we may repurchase up to $ 600.0 million of shares of our common stock. As of December 31, 2023, we repurchased approximately 9.1 million shares of common stock for $ 458.0 million, or $ 50.35 per share, under the Rule 10b5-1 repurchase plan. In total, as of December 31, 2023, we repurchased 16.2 million shares of common stock for $ 802.5 million, or $ 49.49 per share, under the Repurchase Program. No common stock was purchased during the years ended December 31, 2023 or December 31, 2022. </context> | us-gaap:TreasuryStockValueAcquiredCostMethod |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.